Association of Serum Fetuin-A With Insulin Resistance in Type 2 Diabetic and Nondiabetic Subjects
F etuin-A (␣2-Heremans Schmid glycoprotein) is a circulating glycoprotein that can inhibit insulin receptor autophosphorylation and subsequent downstream signaling in vitro (1, 2) . Recently, it has been reported (3) that fetuin-A-deficient mice demonstrate enhanced insulin sensitivity. These data indicate that fetuin-A might be a negative regulator of insulin signaling. However, the physiological significance of fetuin-A in insulin resistance in humans remains unclear.
To address this, we investigated the relationship of serum fetuin-A levels and insulin resistance in nondiabetic (n ϭ 160) and type 2 diabetic (n ϭ 161) subjects. Serum fetuin-A was measured by an enzyme-linked immunosorbent assay kit (BioVender Laboratory Medicine, Brno, Czech Republic) in nondiabetic subjects , fasting plasma glucose 8.2 Ϯ 2.2 mmol/l, and HbA 1c 8.6 Ϯ 1.9%). Insulin resistance was evaluated by homeostasis model assessment (HOMA) of insulin resistance in both groups of subjects and by the M/I value assessed using the hyperinsulinemiceuglycemic clamp in type 2 diabetic subjects.
There were no differences of fetuin-A levels between the nondiabetic and type 2 diabetic groups (260.0 Ϯ 45.0 vs. 260.1 Ϯ 44.1 g/ml, respectively). In simple regression analyses, serum fetuin-A levels were significantly correlated with log(HOMA) in nondiabetic subjects (r ϭ 0.197, P ϭ 0.014). To explore the impact of serum fetuin-A levels on insulin resistance in nondiabetic subjects, multiple regression analyses were performed in which log(HOMA) was included as a dependent variable and BMI, sex, age, triglycerides, and fetuin-A as independent variables. Fetuin-A (␤ ϭ 0.197, P ϭ 0.004) showed a strong independent contribution to log(HOMA) as well as BMI (␤ ϭ 0.369, P Ͻ 0.0001) and triglyceride level (␤ ϭ 0.298, P Ͻ 0.0001) in this model (R 2 ϭ 0.345, P Ͻ 0.0001). However, no significant relationships were observed between fetuin-A levels and log(HOMA) in type 2 diabetic subjects (r ϭ 0.010, P ϭ 0.909), nor were fetuin-A levels correlated with M/I values (r ϭ Ϫ0.068, P ϭ 0.410).
The present study first demonstrates the independent impact of fetuin-A on insulin resistance in nondiabetic subjects. On the other hand, we found a lack of significant association of fetuin-A with insulin resistance in type 2 diabetic subjects. Under diabetic conditions, it might be due to the existence of stronger determinants such as glucose toxicity and/or protein modifications such as nonenzymatic glycation that overcome and veil the effect of fetuin-A on insulin resistance. Or, pharmacological treatment for diabetic subjects may affect fetuin-A levels, although the precise mechanism to regulate them is not yet clear. Since an in vitro study has shown that phosphorylated fetuin has stronger inhibitory effects in insulin receptor autophosphorylation (1) , further studies will be needed to investigate the association of phosphorylated fetuin-A levels with insulin resistance. In conclusion, fetuin-A could be a modulator of insulin resistance in humans. 
